Document:

<PAGE>   1
                                                                   Exhibit 10.15

                 SALES AND MARKETING AGREEMENT FOR UHTS PRODUCTS
                 -----------------------------------------------

This is an Agreement, effective this 21st day of February, 2000, between Carl
Zeiss Jena GmbH, Carl-Zeiss-Promenade 10, 07745 Jena, Germany (hereinafter
ZEISS) and Cellomics, Inc., 635 William Pitt Way, Pittsburgh, PA 15238, USA
(hereinafter CELLOMICS);

        WHEREAS, ZEISS has expertise and intellectual property in developing and
manufacturing of "HTS/UHTS Readers" and "HTS/UHTS Systems" for the market of
drug discovery.

        WHEREAS, CELLOMICS has expertise in application and marketing of assays
and instrumentation in the area of High Content Screening which is a part of the
drug discovery process.

        NOW, THEREFORE, in consideration of the covenants and conditions
contained herein, the parties, intending to be legally bound, agree as follows:

                                    ARTICLE I

                                   DEFINITIONS

         Specific Definitions. For purposes of this Agreement, the following
definitions shall apply:

         1.1 "HTS" and "UHTS" shall mean  [*]

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               1
<PAGE>   2

         1.2 "North America" shall mean the countries of: USA, Canada.

         1.3 "Net Sales Value" shall mean the amount invoiced to the customer.

         1.4 "Rule of Sixths" shall mean that method of calculation of
compensation for out-of-territory sales by either party as set forth on Exhibit
1.0.

                                   ARTICLE II

                               MARKETING AND SALES

         2.1 ZEISS hereby appoints CELLOMICS to be ZEISS' exclusive dealer and
distributor within North America for the items listed in Exhibit 2.0 and for
accessories for such items (such items and accessories being hereinafter
referred to as "Products"); and CELLOMICS hereby accepts such appointment.

         2.2 ZEISS and CELLOMICS will use their best efforts to convince
customers to place orders with CELLOMICS for Products to be installed in North
America and with ZEISS for Products to be installed outside North America.  [*]

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               2
<PAGE>   3

         2.3 [*]

         2.4 Production of literature, production of advertising and
presentation materials for the Products shall be the sole responsibility of
ZEISS with input from CELLOMICS.

         2.5 CELLOMICS shall have the sole responsibility for advertising
placements, shows, and other promotional activities regarding the Products in
North America. Therefore, CELLOMICS shall participate at shows such as but not
limited to LabAutomation, Drug Discovery, and SBS. In the case of advertising
placement and exhibitions which address the international community of the drug
development market (such as advertisements in the Journal of Biomolecular
Screening and presentations at exhibitions such as mentioned above) ZEISS will
provide a proposal which CELLOMICS shall not unreasonably refuse to implement.
In addition, ZEISS reimburses Cellomics a percentage of the total costs incurred
by CELLOMICS. Such percentage shall be negotiated prior to such activity. It is
understood that the ZEISS logo and name shall be shown at these activities.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               3
<PAGE>   4

         2.6 Training of CELLOMICS personnel for Product application and
software support will be provided by ZEISS in Jena. Each party will bear its own
cost with respect to such training and support. If requested by CELLOMICS, ZEISS
will provide training for any new products added to Exhibit 2.0 by mutual
written agreement of the parties.

         2.7 Leads for potential customers obtained by CELLOMICS for potential
sales outside North America will be passed directly to ZEISS. Leads for
potential customers obtained by ZEISS for potential sales in North America will
be passed directly to CELLOMICS. CELLOMICS agrees to provide ZEISS with
exhibition and conference reports. Additionally, CELLOMICS agrees to provide
ZEISS with the minutes of customer contacts with regard to the Products if they
relate to potential leads outside North America, on a timely basis. ZEISS agrees
to provide such reports of customer contacts with regard to the Products if they
relate to potential leads in North America on a timely basis.

         2.8 CELLOMICS shall purchase within the measurement periods described
in Exhibit 3.0 a minimum Deutsche Mark volume based on transfer prices equal to
the sum described in Exhibit 3.0. In the event CELLOMICS fails to purchase such
minimum volume in accordance with this Article and Exhibit 3.0, ZEISS shall
review with CELLOMICS in a management meeting the purchases, open orders, and
deliveries, within a period beginning at the end of such measurement period and
ending thirty (30) days thereafter. After this meeting, ZEISS shall be entitled
to terminate CELLOMICS exclusivity under Section 2.1 of this Agreement or, at
ZEISS's option, to terminate this Agreement in its entirety as a material breach
under Section 5.2 hereof. Any such election by ZEISS shall be by written notice
to CELLOMICS . In the event of such termination of the Agreement in its
entirety, CELLOMICS will receive compensation in the amount of 10% of the Net
Sales Value for sales occurring in North America within six (6) months of
termination and with regard to which CELLOMICS can prove the acquisition of the
sale by CELLOMICS (e.g. by proof that CELLOMICS has

                                                                               4
<PAGE>   5

made an offer to such customer). Such compensation shall be due after full
payment by the customer to ZEISS.

         The parties shall agree upon further annual measuring periods and
minimum volumes not later than six (6) months prior to the expiration of the
last measuring period according to Exhibit 3.0.

         2.9 CELLOMICS will present its non binding sales projection for the
Products in North America for the next business year (October 1 - September 30)
6 months prior to such business year.

         2.10 During the term of this Agreement CELLOMICS shall not sell within
North America any merchandise which is competitive with any of the Products.
CELLOMICS will promptly notify ZEISS whenever it sells any merchandise of a
business which is in competition with ZEISS. In the event CELLOMICS fails to
comply with Section 2.10, ZEISS shall be entitled to terminate CELLOMICS
exclusivity under Section 2.1 of this Agreement immediately. The ArrayScan II,
ArrayScan Kinetics Workstation, ArrayScan Kinetics Reader, CellChip system, and
any and all Cellomics reagents are acknowledged to be not competitive with any
of the Products.

         2.11 ZEISS will deliver any Products FCA Frankfurt (Incoterms 1990).
The parties hereto agree that title to the Products ordered by CELLOMICS will
pass to CELLOMICS at Frankfurt, Germany.

                                                                               5
<PAGE>   6

                                   ARTICLE III

                                CUSTOMER SUPPORT

         3.1 The parties recognize that the marketing and sales of the Products
will require certain support activities and agree to allocate those support
activities in accordance with this Article.

         3.2 CELLOMICS will be responsible for providing Product support in
North America. Product support will include shipping, installation, warranty in
accordance with Exhibit 4.0 and service of the Products at its expense.

         3.3 CELLOMICS shall inform ZEISS prior to the installation of Products
of the basic customer data enabling ZEISS to provide remote service support.

         3.4 ZEISS will train a reasonable number of CELLOMICS' skilled service
personnel in order to be qualified to provide advice to customers in the
operation of the Products and to provide Product support. Each party will bear
its own costs with respect to such training and support.

         3.5 CELLOMICS shall provide Product support to  [*]  by establishing a
service team consisting of at least two skilled service technicians. The service
requirements for the  [*]  are defined in Exhibit 5.0 and CELLOMICS agrees to
fulfill all obligations in accordance with Exhibit 5.0 except installation as
described in section 2 of Exhibit 5.0 and except that ZEISS shall retain
responsibility for replacement of defective parts as described in sections 3 and
4 in Exhibit 5.0 and that except that ZEISS retains responsibility for the terms
of section 5.0 and 10.0 of Exhibit 5.0. At least one service technician shall
take over the responsibility for  [*]  before the end of [*] and shall
participate in a systems training in Jena [*] to [*] by ZEISS in accordance with
Section 3.4. A second service technician shall be assigned to the  [*]  site
before the end of [*].

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               6
<PAGE>   7
         ZEISS shall pay to CELLOMICS the amount of  [*]  in two equal
installments. The first installment shall be due 30 days after the signing of
this Agreement. The second installment shall be due 30 days after CELLOMICS has
notified ZEISS in writing that it has named both service persons and assigned
him/her to the two tasks. If either  [*]  installations require more than  [*]
of service time per year, including travel, ZEISS shall reimburse CELLOMICS for
service beyond  [*]  per system per year at a rate of $75.00 per hour,
plus travel expenses.

         The parties agree that CELLOMICS shall have no further claims against
ZEISS resulting from the fulfillment of CELLOMICS' obligations according to
Exhibit 5.0. CELLOMICS shall not bill any services according to Exhibit 5.0 to
[*]  except for the services described in Section 6 of Exhibit 5.0. In the event
CELLOMICS fails to fulfill its obligations under Exhibit 5.0, ZEISS will notify
CELLOMICS of such failure in writing and CELLOMICS will be given reasonable
opportunity to remedy the notification of failure. CELLOMICS shall reimburse
ZEISS for any costs incurred at ZEISS resulting from such failure at a rate of
$75.00 per hour, plus travel expenses up to a maximum of USD 100,000. Any
obligation resulting from Section 3.5 becomes only effective if confirmed in
writing by ZEISS within 60 days separately from this Agreement.

                                   ARTICLE IV

                                    PRICING

         4.1 The prices for the Products sold by ZEISS to CELLOMICS are the
transfer prices listed on Exhibit 2.0. CELLOMICS understands that prices set
forth in Exhibit 2.0 will be recalculated by ZEISS at the beginning of each
measurement period after the first measurement period. Recalculated prices will
be limited to a maximum of 110% of the previous year's price. The invoices will
be issued in the currency of Deutsche Mark.

         4.2 It is understood that CELLOMICS is free to set its own sales price
in the marketplace.

         4.3 All revenues from sales of the Products by CELLOMICS in North
America will be retained by CELLOMICS.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               7
<PAGE>   8

         4.4 The payment terms are: forty-five (45) days net for the "HTS/UHTS
Reader" and for a "HTS/UHTS System" 70% of its transfer price within forty-five
(45) days net after the date of shipment to either CELLOMICS or the customer and
30% forty five (45) days net after installation at the customer.

         4.5 ZEISS shall provide demonstration equipment at the request of
CELLOMICS and after mutual agreement as to the choice of equipment and
accessories. ZEISS will issue a quarterly invoice for the loaned equipment based
on a monthly rate of one percent (1%) of the transfer price. After 12 months
CELLOMICS shall either return the equipment to ZEISS or purchase it at the
transfer price minus all amounts paid pursuant to the terms of the preceding
sentence including an extra discount of five percent (5%) on the transfer price.
ZEISS will send the loan equipment DDP whereas CELLOMICS will return the
equipment DDP (Incoterms 1990).

CELLOMICS shall accept the loan at any time during this Agreement for at least
two (2) "UHTS/HTS" Readers for demonstration purposes.

                                    ARTICLE V

                              TERM AND TERMINATION

         5.1 The parties agree that this Agreement shall, unless sooner
terminated, continue in effect until December 31, 2005. Notwithstanding the
foregoing, the parties agree that this Agreement may be terminated by either
party on not less than twelve months written prior notice to the other.

         5.2 Either party may terminate this Agreement upon material breach by
the other party. The party intending to terminate shall give the other party
written notice, and the party receiving the notice shall have thirty (30) days
from the date such notice is received to cure any breach.

                                                                               8
<PAGE>   9

In the event such breach is not cured, termination of this Agreement shall
become effective one hundred twenty (120) days after the date of the receipt of
the termination notice. Failure by CELLOMICS to purchase minimum volumes as
described in Section 2.8 and Exhibit 3.0 shall constitute a material breach
unless such failure is a result of ZEISS inability to fulfill orders submitted
by CELLOMICS and, provided that, in order to exercise its right of termination
pursuant to this sentence, ZEISS must give CELLOMICS written notice of such
election within a thirty (30) day period immediately following the close of the
measurement period according to Exhibit 3.0 in which CELLOMICS shall have failed
to meet such minimum volumes. Either party may terminate this Agreement with
immediate effect in the event the other party comes under control of a
competitor of the terminating party.

         5.3 After termination, the parties agree to continue cooperating with
each other and to carry out an orderly termination of their relations. After
termination, the parties shall account to each other for all revenues and
expenses realized, due or owing pursuant to the terms of this Agreement.

         5.4 After termination of this Agreement, CELLOMICS shall cease to
market the Products in North America in any way, except for inventory on hand,
and the parties shall deliver to each other all materials and documents
belonging to the other which have come into their possession as a result of this
Agreement, and CELLOMICS shall cease all and any use of the commercial
trademarks and/or names of ZEISS, except as permitted under other contracts.

         5.5 CELLOMICS shall have the right to liquidate its stock of software
and hardware, and any promotional material relating thereto, in the event of
termination. In the event CELLOMICS terminates this Agreement without cause or
ZEISS terminates this Agreement due to a material breach by CELLOMICS then ZEISS
may accept but shall not be obligated to repurchase spare parts purchased by
CELLOMICS. In the event ZEISS terminates this Agreement without cause or
CELLOMICS terminates this Agreement due to a material breach by ZEISS then
CELLOMICS may return any spare parts within thirty (30) days after

                                                                               9

<PAGE>   10

termination to ZEISS in the original packing. ZEISS shall then pay to CELLOMICS
an amount equivalent to the price paid by CELLOMICS before minus 15% restocking
fee.

         5.6 In the event of termination, all CELLOMICS' held customer related
information will remain the sole property of CELLOMICS except as specified in
Section 3.3.

                                   ARTICLE VI

                                 CONFIDENTIALITY

         6.1 Prior to and during the term of this Agreement, the parties will
disclose to each other certain confidential or proprietary information
("INFORMATION"), the disclosure of which to third parties could be commercially
injurious to the owner of the INFORMATION.

         6.2 The disclosure of the INFORMATION is solely for the purpose of the
furtherance of the marketing and sale of the Products and services described
herein.

         6.3 Each party understands that the disclosing party considers the
INFORMATION to be confidential and a trade secret.

         6.4 Each party will not disclose to any third party, or utilize for its
own or another's benefit, the INFORMATION obtained from the disclosing party.

         6.5 The term "INFORMATION" shall not include, and the parties shall not
have any obligations of confidence or non-disclosure with respect to:

                  6.5.1 information that is in the public domain at the time of
                  its transmittal or which subsequently comes into the public
                  domain without violation of any obligation of confidence
                  assumed hereunder; or

                  6.5.2 information received from a third party without
                  violation of an obligation of confidence to the transmitting
                  party; or

                  6.5.3 information which the recipient party can show to have
                  been in its possession at the time of transmittal; or

                                                                              10
<PAGE>   11
                  6.5.4 information which the recipient party can show to have
                  been independently developed by employees of the recipient
                  party who have not had access to proprietary information
                  received hereunder; or

                  6.5.5 information which the recipient party is compelled to
                  disclose pursuant to judicial action or the legal and
                  enforceable request of a U.S. government agency, provided that
                  the transmitting party is notified at the time such action or
                  request is initiated, and further provided that the recipient
                  party cooperates with the transmitting party in the event that
                  the transmitting party seeks a protective order or other
                  appropriate remedy to prevent disclosure of such information.

         6.6 If either party believes it essential to disclose any INFORMATION
to a third party, the party wishing to disclose will first advise the other
party what INFORMATION is to be disclosed, to whom it is to be disclosed and the
purpose therefore. The party wishing to disclose will first obtain the other
party's written permission to make the disclosure before making such disclosure,
which permission may be withheld for any reason. The requesting party also
agrees to require the third party recipient of the INFORMATION to acknowledge
that such INFORMATION is confidential, to hold the INFORMATION confidential for
the benefit of the disclosing party, and to sign a copy of a protective
agreement, naming the disclosing party as a third-party beneficiary having the
right to enforce the Agreement against the third party.

         6.7 All INFORMATION, where possible, shall be transferred from each
party to the other in written form, and shall bear a conspicuous mark
designating such INFORMATION to be confidential. Additionally, any INFORMATION
transferred from each party to the other in an oral or other non-permanent or
non-readable form, such as in a computer communication, shall be summarized in a
brief memorandum which shall also bear a conspicuous mark designating such
INFORMATION to be confidential. Furthermore, all INFORMATION transferred in
tangible form shall be returned to the disclosing party upon request and/or at
the termination of this Agreement.

                                                                              11
<PAGE>   12

         6.8 It is understood that this Agreement will neither obligate either
party, nor grant to either party or any employees thereof, any rights in the
INFORMATION, or any protectable interest stemming therefrom, during the term of
the Agreement, except as specifically provided herein.

         6.9 Each party agrees that if it or any of its employees breaches any
condition of this Agreement relating to the protection of proprietary or
confidential rights or information, the owner of such right or information will
be entitled to, in addition to all other remedies available, an immediate
injunction prohibiting the party in breach of its obligations, or its employees,
partners or other business associates, from committing any further breach of the
Agreement.

                                   ARTICLE VII

                           WARRANTIES AND DISCLAIMERS

         7.1 Each party represents and warrants to the other party that it has
no pre-existing contractual or other obligations to any third party which
preclude it from entering into this Agreement and meeting its obligations
hereunder, or which conflict with any Provision of this Agreement.

         7.2 Each party represents and warrants to the other party that it shall
use any commercially reasonable efforts to achieve the objectives of the
Agreement.

                                  ARTICLE VIII

                    TRADEMARKS, SERVICE MARKS AND TRADE NAMES

         8.1 CELLOMICS must obtain ZEISS's prior written approval for the design
of CELLOMICS's sales materials, letterheads forms, etc. bearing the name or the
trademarks of

                                                                              12
<PAGE>   13

ZEISS. CELLOMICS shall have the right to use the ZEISS's name and trademarks
solely in the manner for which it has obtained ZEISS's approval and only during
the term of this Agreement and such approvals will be made in a timely manner
and not unreasonably withheld, except as provided in other contracts.

                                   ARTICLE IX

                                  MISCELLANEOUS

9.1 Governing Law

         This Agreement shall be construed in accordance with the laws of the
State of New York applicable to contracts made and performed in New York.

9.2 Actions Survive

         All causes of action accruing to either party under this Agreement
shall survive termination for any reason, as shall provisions which expressly
state such survival unless such survival is conditional and the requisite
condition(s) has been fulfilled prior to or on such termination.

9.3 Entire Agreement; Superseder; Section Headings, Construction

         This Agreement constitutes the only and entire understanding between
the parties concerning its subject matter and all other prior negotiations,
representations, agreements and understandings are superseded hereby. No
agreements altering or supplementing the terms hereof may be made except by
means of a written document signed by the duly authorized representatives of the
parties. The headings of Sections in this Agreement are provided for convenience
only and will not affect its construction or interpretation.

9.4 Amendments

         This Agreement may be amended or modified only in writing, signed by
both parties.

                                                                              13
<PAGE>   14

9.5 Independent Contractor

         Each party shall have the status of an independent contractor without
the authority to bind the other to any obligation.

9.6 Arbitration

         All disputes which arise out of this Agreement shall be settled by
arbitration in Westchester County, New York in accordance with the conciliation
and arbitration rules and regulations of the American Arbitration Association,
to which the parties hereto submit including the AAA Optional Rules for
Emergency Measures of Protection to preserve the status quo ante of the parties.
The arbitrator shall have background and expertise relating to the issue(s)
involved. The arbitration shall be in English. The arbitration hearing shall be
held within sixty days of an arbitration demand. The arbitrator's decision shall
be submitted within thirty (30) days of the conclusion of the arbitration
hearing. The arbitrator's decision shall be binding, final and non-appealable.
The parties shall share equally the cost of such arbitration. Any and all
actions necessary to compel arbitration or to enforce the decision of the
arbitrator or any aspect thereof shall be brought in the state or federal courts
of Westchester County, New York and the parties specifically agree that the
state and federal courts of or pertaining to Westchester County, New York shall
have and the parties submit to the exclusive jurisdiction and venue of such
courts.

9.7 Force Majeure

         If either party is prevented from performing any obligation hereunder
by reason of fire, explosion, strike, labor dispute, casualty, accident, lack or
failure of transportation facilities, flood, war, civil commotion, acts of God,
or any law, order or decree of any government or subdivision thereof, then such
party shall be excused from performance hereunder to the extent

                                                                              14
<PAGE>   15
and for the duration of such prevention, provided that such party notifies the
other party in writing of such prevention in a manner which is timely under the
circumstances.

9.8 Publicity

         Except as required by law or applicable stock exchange rule, no public
statements shall be made by either party concerning this Agreement, its subject
matter or its existence without prior consultation with and the approval of the
other party, which approval shall not be unreasonably withheld. In the event
CELLOMICS undertakes an initial or subsequent public offering of its stock,
ZEISS agrees to review and give its approval to necessary statements regarding
the existence and/or subject matter of this Agreement within twenty four (24)
hours (but not less than one business day) of its receipt of a draft of the
proposed language regarding this Agreement and ZEISS shall not unreasonably
withhold such approval.

9.9 Severability

         In the event that any Provision of this Agreement shall be found to be
illegal, invalid or unenforceable for any reason, such shall not affect the
validity of the remainder of this Agreement, which shall be construed and
interpreted as though such Provision was not present.

9.10 Notices

         Notices may be given to an officer of a party by:

                  A. personal delivery,

                  B. telex or telecopy or

                  C. certified or registered mail addressed or

                                                                              15
<PAGE>   16

                  D. overnight delivery by an internationally recognized courier
                     service as follows:

If to ZEISS:        Dr. Norbert Gorny           and        Dr. Robert A. Grub
                    Carl Zeiss Jena, GmbH                  Microscopy Division
                    Carl-Zeiss-Promenade 10                Carl Zeiss Jena, GmbH
                    07740 Jena, Germany                    07740 Jena, Germany

                    with a copy to:    Carl Zeiss Inc.
                                       James Kelly
                                       One Zeiss Drive
                                       Thornwood, NY 10594

If to CELLOMICS:    D. Lansing Taylor, Ph.D.
                    President & Chief Executive Officer
                    635 William Pitt Way
                    Pittsburgh, PA 15238

                    with a copy to:    Sweeney Metz Fox McGrann & Schermer
                                       The Westinghouse Building - 18th Floor
                                       11 Stanwix Street
                                       Pittsburgh, PA 15222

9.11 Binding Effect

         This Agreement shall inure to the benefit of and be binding on each
party's successors in interest and assigns.

                                                                              16
<PAGE>   17

9.12 Assignment

         The parties understand and agree that as soon as practicable after
execution of this Agreement CELLOMICS will assign all benefits, rights,
responsibilities and obligations of this Agreement to a soon to be formed wholly
owned subsidiary of CELLOMICS, which the parties anticipate will be incorporated
in the Cayman Islands, the European Economic Community or other jurisdiction
outside of the United States of America; such assignment shall be specifically
required and permitted. Except as provided in the preceding sentence, either
party may assign this Agreement only in connection with the sale or disposition
of the entire business of such party or that portion to which this Agreement
pertains. Either party may assign this Agreement to an Affiliate(s) without
permission of the other party. Affiliate shall mean an entity controlling,
controlled by, or under common control with a party to this Agreement. ZEISS
shall be entitled to refuse ist consent to an assignment in the event the
Affiliate of CELLOMICS is a competitor of ZEISS.

9.13 Exhibits

         The following Exhibits form an integral part of this Agreement:

Exhibit 1.0: Rule of Sixths

Exhibit 2.0: Products and Transfer Prices

Exhibit 3.0: Minimum Volumes.

Exhibit 4.0: Limited Warranty

Exhibit 5.0: [*]

         IN WITNESS WHEREOF, this Agreement has been executed in multiple
counterparts, each of which shall constitute an original Agreement, on behalf of
the parties by their authorized officers as of the date first written above.

                                                                              17
<PAGE>   18

CARL ZEISS JENA GMBH

By

Its

Date

CELLOMICS , INC.

By

Its

Date

                                                                              18<PAGE>   1
                                                                   Exhibit 10.16

                                 CELLOMICS, INC.

                                 2000 STOCK PLAN

         1. Purposes of the Plan. The purposes of this Stock Plan are to attract
and retain the best available personnel for positions of substantial
responsibility, to provide additional incentive to Employees, non-Employee
members of the Board and Consultants of the Company and its Parent and
Subsidiaries and to promote the success of the Company's business. Options
granted under the Plan may be incentive stock options (as defined under Section
422 of the Code) or non-statutory stock options, as determined by the
Administrator at the time of grant of an option and subject to the applicable
provisions of Section 422 of the Code, as amended, and the regulations
promulgated thereunder. Stock purchase rights, stock grants and stock
appreciation rights may also be granted under the Plan.

         2. Certain Definitions. As used herein, the following definitions shall
apply:

                  (a) "Administrator" means the Board or any of its Committees
appointed pursuant to Section 4 of the Plan.

                  (b) "Award" means any option, stock purchase right, stock
grant or stock appreciation right granted to a Participant under the Plan.

                  (c) "Board" means the Board of Directors of the Company.

                  (d) "Change in Control" means (i) any "person" (as such term
is used in Sections 13(d) and 14(d) of the Exchange Act) through a tender offer,
open market purchases and/or other purchases is or becomes a beneficiary owner,
directly or indirectly, of securities of the Company representing more than
fifty percent (50%) of the combined voting power of the Company's then
outstanding securities or (ii) a majority of the Board shall be comprised of
persons who (x) were elected in one or more contested elections for the Board
and (y) had not been nominated by the then existing Board when they were first
elected to the Board.

                  (e) "Code" means the Internal Revenue Code of 1986, as
amended.

                  (f) "Committee" means the Committee appointed by the Board of
Directors in accordance with paragraph (a) of Section 4 of the Plan.

                  (g) "Common Stock" means the Common Stock of the Company.

                  (h) "Company" means Cellomics, Inc., a Delaware corporation.

<PAGE>   2

                  (i) "Consultant" means any person, including an advisor, who
is engaged by the Company or any Parent or Subsidiary to render services and is
compensated for such services, and any director of the Company whether
compensated for such services or not.

                  (j) "Continuous Status as an Employee" means the absence of
any interruption or termination of the employment relationship by the Company or
any Parent or Subsidiary. Continuous Status as an Employee shall not be
considered interrupted in the case of: (i) sick leave; (ii) military leave;
(iii) any other leave of absence approved by the Board, provided that such leave
is for a period of not more than ninety (90) days, unless reemployment upon the
expiration of such leave is guaranteed by contract or statute, or unless
provided otherwise pursuant to Company policy adopted from time to time; or (iv)
transfers between locations of the Company or between the Company, its Parent,
its Subsidiaries or its successor.

                  (k) "Employee" means any person, including officers and
directors, employed by the Company or any Parent or Subsidiary of the Company.
The payment of a director's fee by the Company shall not be sufficient to
constitute "employment" by the Company.

                  (l) "Exchange Act" means the Securities Exchange Act of 1934,
as amended.

                  (m) "Fair Market Value" means, as of any date, the value of
Common Stock determined as follows:

                           (i) If the Common Stock is listed on any established
         stock exchange or a national market system including, without
         limitation, the National Market System of the National Association of
         Securities Dealers, Inc. Automated Quotation ("Nasdaq") System, its
         Fair Market Value shall be the closing sales price for such stock (or
         the closing bid, if no sales were reported) as quoted on such system or
         exchange for the last market trading day prior to the time of
         determination as reported in the Wall Street Journal or such other
         source as the Administrator deems reliable or;

                           (ii) If the Common Stock is quoted on Nasdaq (but not
         on the National Market System thereof) or regularly quoted by a
         recognized securities dealer but selling prices are not reported, its
         Fair Market Value shall be the mean between the high and low asked
         prices for the Common Stock or;

                           (iii) In the absence of an established market for the
         Common Stock, the Fair Market Value thereof shall be determined in good
         faith by the Administrator.

                  (n) "Incentive Stock Option" means an Option intended to
qualify as an incentive stock option within the meaning of Section 422 of the
Code.

                  (o) "Nonstatutory Stock Option" means an Option not intended
to qualify as an Incentive Stock Option.

                                      -2-
<PAGE>   3

                  (p) "Option" means a stock option granted pursuant to the
Plan.

                  (q) "Optioned Stock" means the Common Stock subject to an
Option.

                  (r) "Optionee" means an Employee or Consultant who receives an
Option.

                  (s) "Parent" means a "parent corporation", whether now or
hereafter existing, as defined in Section 424(e) of the Code.

                  (t) "Participant" means an Employee, non-Employee Member of
the Board or Consultant who receives an Award under the Plan.

                  (u) "Plan" means this 2000 Stock Plan.

                  (v) "Restricted Stock" means shares of Common Stock acquired
pursuant to a grant of stock or stock purchase rights under Section 11 below.

                  (w) "SAR" means a stock appreciation right, which is the right
to receive an amount equal to the appreciation, if any, in the Fair Market Value
of a Share from the date of the grant of the right to the date of its payment,
as adjusted in accordance with Section 13 of the Plan.

                  (x) "Share" means a share of the Common Stock, as adjusted in
accordance with Section 13 of the Plan.

                  (y) "Subsidiary" means a "subsidiary corporation", whether now
or hereafter existing, as defined in Section 424(f) of the Code.

         3. Stock Subject to the Plan. Subject to the provisions of Section 13
of the Plan, the maximum aggregate number of Shares which may be optioned,
issued or sold under the Plan is 330,000 Shares of Common Stock. The Shares may
be authorized, but unissued Shares, reacquired Shares, Shares acquired on the
open market specifically for distribution under this Plan, or any combination
thereof.

                  If an Option or SAR should expire or become unexercisable for
any reason without having been exercised in full, or if shares of Restricted
Stock are forfeited, the unused Shares which were subject thereto shall, unless
the Plan shall have been terminated, become available for future grant under the
Plan.

         4. Administration of the Plan.

                  (a) Procedure.

                           (i) Administration With Respect to Directors and
                  Officers. With respect to grants of Awards to Employees who
                  are also officers or directors of the

                                      -3-
<PAGE>   4

                  Company, the Plan shall be administered by (A) the Board, if
                  the Board may administer the Plan in compliance with Rule
                  16b-3 promulgated under the Exchange Act or any successor
                  thereto ("Rule 16b-3") with respect to a plan intended to
                  qualify thereunder as a discretionary plan, or (B) a Committee
                  designated by the Board to administer the Plan, which
                  Committee shall be constituted in such a manner as to permit
                  the Plan to comply with Rule 16b-3 with respect to a plan
                  intended to qualify thereunder as a discretionary plan. Once
                  appointed, such Committee shall continue to serve in its
                  designated capacity until otherwise directed by the Board.
                  From time to time the Board may increase the size of the
                  Committee and appoint additional members thereof, remove
                  members (with or without cause) and appoint new members in
                  substitution therefor, fill vacancies, however caused, and
                  remove all members of the Committee and thereafter directly
                  administer the Plan, all to the extent permitted by Rule 16b-3
                  with respect to a plan intended to qualify thereunder as a
                  discretionary plan.

                           (ii) Multiple Administrative Bodies. If permitted by
                  Rule 16b-3, the Plan may be administered by different bodies
                  with respect to directors, non-director officers and Employees
                  who are neither directors nor officers.

                           (iii) Administration With Respect to Consultants and
                  Other Employees. With respect to grants of Awards to Employees
                  who are neither directors nor officers of the Company or to
                  Consultants, the Plan shall be administered by (A) the Board,
                  if the Board may administer the Plan in compliance with Rule
                  16b-3, or (B) a Committee designated by the Board, which
                  Committee shall be constituted in such a manner as to satisfy
                  the legal requirements relating to the administration of
                  incentive stock option plans, if any, of applicable securities
                  laws and of the Code (the "Applicable Laws"). Once appointed,
                  such Committee shall continue to serve in its designated
                  capacity until otherwise directed by the Board. From time to
                  time the Board may increase the size of the Committee and
                  appoint additional members thereof, remove members (with or
                  without cause) and appoint new members in substitution
                  therefor, fill vacancies, however caused, and remove all
                  members of the Committee and thereafter directly administer
                  the Plan, all to the extent permitted by the Applicable Laws.

                  (b) Powers of the Administrator. Subject to the provisions of
the Plan and in the case of a Committee, the specific duties delegated by the
Board to such Committee, the Administrator shall have the authority, in its
discretion:

                           (i) to determine the Fair Market Value of the Common
                  Stock, in accordance with Section 2(l) of the Plan;

                           (ii) to select the officers, Consultants and
                  Employees to whom Awards may from time to time be granted
                  hereunder;

                           (iii) to determine whether and to what extent
                  Options, stock grants, stock purchase rights or SARs, or any
                  combination thereof, are granted hereunder;

                                      -4-
<PAGE>   5

                           (iv) to determine the number of shares of Common
                  Stock to be covered by each such Award granted hereunder;

                           (v) to approve forms of agreement for use under the
                  Plan;

                           (vi) to determine the terms and conditions, not
                  inconsistent with the terms of the Plan, of any Award granted
                  hereunder (including, but not limited to, the share price and
                  any restriction or limitation or waiver of forfeiture
                  restrictions regarding any Option or other Award and/or the
                  shares of Common Stock relating thereto, based in each case on
                  such factors as the Administrator shall determine, in its sole
                  discretion);

                           (vii) to determine whether and under what
                  circumstances an Option or SAR may be settled in cash under
                  subsection 9(f) instead of Common Stock;

                           (viii) to determine whether, to what extent and under
                  what circumstances Common Stock and other amounts payable with
                  respect to an Award under this Plan shall be deferred either
                  automatically or at the election of the participant (including
                  providing for and determining the amount, if any, of any
                  deemed earnings on any deferred amount during any deferral
                  period);

                           (ix) to reduce the exercise price of any Option or
                  SAR to the then current Fair Market Value if the Fair Market
                  Value of the Common Stock covered by such Option or SAR shall
                  have declined since the date the Option or SAR was granted;

                           (x) to determine the terms and restrictions
                  applicable to stock grants, stock purchase rights and the
                  Restricted Stock granted by such stock grant or purchased by
                  exercising such stock purchase rights; and

                           (xi) in its discretion, upon a Change in Control to
                  vest and make exerciseable any Award granted hereunder which
                  is not fully vested or exercisable and to remove any
                  restrictions on Restricted Stock effective upon the occurrence
                  of a Change in Control or the termination of a Participant's
                  service to the Company.

                  (c) Effect of Committee's Decision. All decisions,
determinations and interpretations of the Administrator shall be final and
binding on all Participants and any other holders of any Awards granted
hereunder.

         5. Eligibility.

                  (a) Nonstatutory Stock Options and SARs may be granted to
Employees, non-Employee Members of the Board and Consultants. Incentive Stock
Options may be granted only to Employees. An Employee or Consultant who has been
granted an Option or SAR may, if he is otherwise eligible, be granted additional
Options or SARs.

                                      -5-
<PAGE>   6

                  (b) Each Option shall be designated in the written option
agreement as either an Incentive Stock Option or a Nonstatutory Stock Option.
However, notwithstanding such designations, to the extent that the aggregate
Fair Market Value of the Shares with respect to which Options designated as
Incentive Stock Options are exercisable for the first time by any optionee
during any calendar year (under all plans of the Company or any Parent or
Subsidiary) exceeds $100,000, such excess Options shall be treated as
Nonstatutory Stock Options.

                  (c) For purposes of Section 5(b), Incentive Stock Options
shall be taken into account in the order in which they were granted, and the
Fair Market Value of the Shares shall be determined as of the time the Option
with respect to such Shares is granted.

                  (d) The Plan shall not confer upon any Participant any right
with respect to continuation of employment or consulting relationship with the
Company, nor shall it interfere in any way with his right or the Company's right
to terminate his employment or consulting relationship at any time, with or
without cause.

         6. Term of Plan. The Plan shall become effective upon the earlier to
occur of its adoption by the Board of Directors or its approval by the
shareholders of the Company as described in Section 19 of the Plan. It shall
continue in effect for a term of ten (10) years unless sooner terminated under
Section 15 of the Plan.

         7. Terms of Options and SARs. The term of each Option or SAR shall be
the term stated in the written agreement evidencing such Option or SAR;
provided, however, that in the case of an Incentive Stock Option, the term shall
be no more than ten (10) years from the date of grant thereof or such shorter
term as may be provided in the Option Agreement. However, in the case of an
Option granted to an Optionee who, at the time the Option is granted, owns stock
representing more than ten percent (10%) of the voting power of all classes of
stock of the Company or any Parent or Subsidiary, the term of the Option shall
be five (5) years from the date of grant thereof or such shorter term as may be
provided in the written agreement evidencing such Option.

         8. Option Exercise Price and Consideration.

                  (a) The per share exercise price for the Shares to be issued
pursuant to exercise of an Option shall be such price as is determined by the
Board, but shall be subject to the following:

                           (i) In the case of an Incentive Stock Option

                           (A) granted to an Employee who, at the time of the
                  grant of such Incentive Stock Option, owns stock representing
                  more than ten percent (10%) of the voting power of all classes
                  of stock of the Company or any Parent or Subsidiary, the per
                  Share exercise price shall be no less than 110% of the Fair
                  Market Value per Share on the date of grant.

                                      -6-
<PAGE>   7

                           (B) granted to any Employee, the per Share exercise
                  price shall be no less than 100% of the Fair Market Value per
                  Share on the date of grant.

                           (ii) In the case of a Nonstatutory Stock Option
                  granted to any person, the per Share exercise price may be
                  less than the Fair Market Value per Share on the date of
                  grant.

                  (b) The consideration to be paid for the Shares to be issued
upon exercise of an Option, including the method of payment, shall be determined
by the Administrator (and, in the case of an Incentive Stock Option, shall be
determined at the time of grant) and may consist entirely of (1) cash, (2)
check, (3) promissory note, (4) other Shares which (x) in the case of Shares
acquired upon exercise of an Option either have been owned by the Optionee for
more than six months on the date of surrender or were not acquired, directly or
indirectly, from the Company, and (y) have a Fair Market Value on the date of
surrender equal to the aggregate exercise price of the Shares as to which said
Option shall be exercised, (5) authorization from the Company to retain from the
total number of Shares as to which the Option is exercised that number of Shares
having a Fair Market Value on the date of exercise equal to the exercise price
for the total number of Shares as to which the option is exercised, (6) delivery
of a properly executed exercise notice together with irrevocable instructions to
a broker to promptly deliver to the Company the amount of sale or loan proceeds
required to pay the exercise price, (7) by delivering an irrevocable
subscription agreement for the Shares which irrevocably obligates the option
holder to take and pay for the Shares not more than twelve months after the date
of delivery of the subscription agreement, (8) any combination of the foregoing
methods of payment, or (9) such other consideration and method of payment for
the issuance of Shares to the extent permitted under Applicable Laws. In making
its determination as to the type of consideration to accept, the Administrator
shall consider if acceptance of such consideration may be reasonably expected to
benefit the Company.

         9. Exercise of Options or SARs.

                  (a) Procedure for Exercise; Rights as a Shareholder. Any
Option or SAR granted hereunder shall be exercisable at such times and under
such conditions as determined by the Administrator, including performance
criteria with respect to the Company and/or the Participant, and as shall be
permissible under the terms of the Plan.

                  An Option or SAR may not be exercised for a fraction of a
Share.

                  An Option or SAR shall be deemed to be exercised when written
notice of such exercise has been given to the Company in accordance with the
terms of the Option or SAR by the person entitled to exercise such Option or SAR
and, if an Option is to be exercised, full payment for the Shares with respect
to which the Option is exercised has been received by the Company. Full payment
may, as authorized by the Administrator, consist of any consideration and method
of payment allowable under Section 8(b) of the Plan. Until the issuance (as
evidenced by the appropriate entry on the books of the Company or of a duly
authorized transfer

                                      -7-
<PAGE>   8

agent of the Company) of the stock certificate evidencing such Shares, no right
to vote or receive dividends or any other rights as a shareholder shall exist
with respect to the Optioned Stock, notwithstanding the exercise of the Option.
The Company shall issue (or cause to be issued) such stock certificate promptly
upon exercise of the Option. No adjustment will be made for a dividend or other
right for which the record date is prior to the date the stock certificate is
issued, except as provided in Section 13 of the Plan.

                  Exercise of an Option or SAR in any manner shall result in a
decrease in the number of Shares which thereafter may be available, both for
purposes of the Plan and for sale under the Option or SAR, by the number of
Shares as to which the Option or SAR is exercised.

                  (b) Termination of Employment. In the event of termination of
a Participant's consulting relationship or Continuous Status as an Employee with
the Company (as the case may be), such Participant may, but only within ninety
(90) days (or such other period of time as is determined by the Board, with such
determination in the case of an Incentive Stock Option being made at the time of
grant of the Option and not exceeding ninety (90) days) after the date of such
termination (but in no event later than the expiration date of the term of such
Option or SAR as set forth in the written agreement evidencing such Option or
SAR), exercise his Option or SAR to the extent that such Participant was
entitled to exercise it at the date of such termination. To the extent that such
Participant was not entitled to exercise the Option or SAR at the date of such
termination, or if such Participant does not exercise such Option or SAR to the
extent so entitled within the time specified herein, the Option or SAR shall
terminate.

                  (c) Disability of Optionee. Notwithstanding the provisions of
Section 9(b) above, in the event of termination of a Participant's consulting
relationship or Continuous Status as an Employee as a result of his total and
permanent disability (as defined in Section 22(e)(3) of the Code), such
Participant may, but only within twelve (12) months (or such other period of
time as is determined by the Board, with such determination in the case of an
Incentive Stock Option being made at the time of grant of the Options and not
exceeding twelve (12) months) from the date of such termination (but in no event
later than the expiration date of the term of such Option or SAR as set forth in
the written agreement evidencing such Option or SAR), exercise the Option or SAR
to the extent otherwise entitled to exercise it at the date of such termination.
To the extent that such Participant was not entitled to exercise the Option or
SAR at the date of termination, or if such Participant does not exercise such
Option or SAR to the extent so entitled within the time specified herein, the
Option or SAR shall terminate.

                  (d) Death of Optionee. In the event of the death of a
Participant, the Option or SAR may be exercised, at any time within twelve (12)
months following the date of death (but in no event later than the expiration
date of the term of such Option or SAR as set forth in the written agreement
evidencing such Option or SAR), by the Participant's estate or by a person who
acquired the right to exercise the Option or SAR by bequest or inheritance, but
only to the extent the Participant was entitled to exercise the Option or SAR at
the date of death. To the

                                      -8-
<PAGE>   9

extent that such Participant was not entitled to exercise the Option or SAR at
the date of death, or if such Participant's estate or any person who acquired
the right to exercise the Option or SAR by bequest or inheritance does not
exercise such Option or SAR to the extent so entitled within the time specified
herein, the Option or SAR shall terminate.

                  (e) Rule 16b-3. Options or SARs granted to persons subject to
Section 16(b) of the Exchange Act must comply with Rule 16b-3 and shall contain
such additional conditions or restrictions as may be required thereunder to
qualify for the maximum exemption from Section 16 of the Exchange Act with
respect to Plan transactions.

                  (f) Buyout Provisions. The Administrator may at any time offer
to buy out for a payment in cash or Shares, an Option or SAR previously granted,
based on such terms and conditions as the Administrator shall establish and
communicate to the Participant at the time that such offer is made.

                  (g) Payout Provisions. At the discretion of the Company, the
payment to a Participant upon exercise of a SAR, may be in cash, in Shares of
equivalent value, or in some combination thereof, subject to the availability of
Shares to the Company under the Plan.

         10. Non-Transferability of Options or SARs. The Option or SAR may not
be sold, pledged, assigned, hypothecated, transferred, or disposed of in any
manner other than by will or by the laws of descent or distribution and may be
exercised, during the lifetime of the Participant, only by the Participant. The
terms of the Option or SAR shall be binding upon the executors, administrators,
heirs, successors and assigns of the Participant.

         11. Stock Grants and Stock Purchase Rights.

                  (a) Awards and Rights to Purchase. Stock grants and stock
purchase rights may be issued to Employees, non-Employee Members of the Board
and Consultants, either alone, in addition to, or in tandem with other Awards
granted under the Plan and/or cash awards made outside of the Plan. After the
Administrator determines that it will make a stock grant or offer stock purchase
rights under the Plan, it shall advise the offeree in writing of the terms,
conditions and restrictions related to the grant or offer, including the number
of Shares that such person shall be granted or entitled to purchase, any
repurchase rights of the Company and the terms thereof and, in the case of a
right to purchase (i) the price to be paid, and (ii) the time within which such
person must accept such offer. The offer shall be accepted by execution of a
Restricted Stock purchase agreement, as the case may be, in the form determined
by the Administrator.

                  (b) Other Provisions. The Restricted Stock grant agreement and
purchase agreement shall contain such other terms, provisions and conditions not
inconsistent with the Plan as may be determined by the Administrator in its sole
discretion. In addition, the provisions of Restricted Stock grant agreements or
purchase agreements need not be the same with respect to each purchaser.

                                      -9-
<PAGE>   10

                  (c) Rights as a Shareholder. Once the stock grant is completed
or a stock purchase right is exercised, the grantee or purchaser shall have the
rights equivalent to those of a shareholder, and shall be a shareholder when his
or her grant or purchase is entered upon the records of the duly authorized
transfer agent of the Company. No adjustment will be made for a dividend or
other right for which the record date is prior to the date the stock grant is
completed or the stock purchase right is exercised, except as provided in
Section 13 of the Plan.

         12. Stock Withholding to Satisfy Withholding Tax Obligations. At the
discretion of the Administrator, Participants may satisfy withholding
obligations as provided in this paragraph. When a Participant incurs tax
liability in connection with an Option, stock grant, stock purchase right or
SAR, which tax liability is subject to tax withholding under applicable tax
laws, and the Participant is obligated to pay the Company an amount required to
be withheld under applicable tax laws, the Participant may satisfy the
withholding tax obligation by electing to have the Company withhold from the
Shares to be issued upon exercise of the Option or SAR, or the Shares to be
issued in connection with the stock grant or stock purchase right, if any, that
number of Shares having a Fair Market Value equal to the amount required to be
withheld. The Fair Market Value of the Shares to be withheld shall be determined
on the date that the amount of tax to be withheld is to be determined (the "Tax
Date").

                  In the event that the Company elects to make a payment to the
Participant in cash upon the exercise of a SAR, the Participant may satisfy the
withholding tax obligation by electing to have the Company withhold from such
payment the amount required to satisfy such withholding tax obligation.

                  All elections by a Participant to have Shares or cash withheld
for this purpose, as the case may be, shall be made in writing in a form
acceptable to the Administrator and shall be subject to the following
restrictions:

                  (a) the election must be made on or prior to the applicable
Tax Date;

                  (b) once made, the election shall be irrevocable as to the
particular Shares of the Option, stock purchase right or SAR, as to which the
election is made;

                  (c) all elections shall be subject to the consent or
disapproval of the Administrator;

                  (d) if the Participant is subject to Rule 16b-3, the election
must comply with the applicable provisions of Rule 16b-3 and shall be subject to
such additional conditions or restrictions as may be required thereunder to
qualify for the maximum exemption from Section 16 of the Exchange Act with
respect to Plan transactions.

                  In the event the election to have Shares or cash withheld is
made by a Participant and the Tax Date is deferred under Section 83 of the Code
because no election is filed under Section 83(b) of the Code, the Participant
shall receive the full number of Shares or full amount

                                      -10-
<PAGE>   11

of cash, as the case may be, with respect to which the Option, stock grant,
stock purchase right or SAR is exercised but such Participant shall be
unconditionally obligated to tender back to the Company the proper number of
Shares, or the proper amount of cash, as the case may be, on the Tax Date.

         13. Adjustments Upon Changes in Capitalization or Merger. Subject to
any required action by the shareholders of the Company, the number of shares of
Common Stock covered by each outstanding Option or SAR, and the number of shares
of Common Stock which have been authorized for issuance under the Plan but as to
which no Options or SARs have yet been granted or which have been returned to
the Plan upon cancellation or expiration of an Option or SAR, as well as the
price per share of Common Stock covered by each such outstanding Option or SAR,
shall be proportionately adjusted for any increase or decrease in the number of
issued shares of Common Stock resulting from a stock split, reverse stock split,
stock dividend, combination or reclassification of the Common Stock, or any
other increase or decrease in the number of issued shares of Common Stock
effected without receipt of consideration by the Company; provided, however,
that conversion of any convertible securities of the Company shall not be deemed
to have been "effected without receipt of consideration." Such adjustment shall
be made by the Board, whose determination in that respect shall be final,
binding and conclusive. Except as expressly provided herein, no issuance by the
Company of shares of stock of any class, or securities convertible into shares
of stock of any class, shall affect, and no adjustment by reason thereof shall
be made with respect to, the number or price of shares of Common Stock subject
to an Option or SAR.

                  In the event of the proposed dissolution or liquidation of the
Company, the Board shall notify the Participant at least fifteen (15) days prior
to such proposed action. To the extent it has not been previously exercised, any
Option or SAR will terminate immediately prior to the consummation of such
proposed action and any restrictions on Restricted Stock shall expire
immediately prior to the consummation of such proposed action. In the event of a
merger or consolidation of the Company with or into another corporation or the
sale of all or substantially all of the Company's assets (each hereinafter, a
"merger"), the Board may authorize outstanding Options or SARs to be assumed or
an equivalent option or stock appreciation right to be substituted by such
successor corporation or a parent or subsidiary of such successor corporation
and may assign any restrictions on Restricted Stock to the successor
corporation. In the event that such successor corporation does not agree to
assume the Option or SAR, or to substitute an equivalent option or stock
appreciation right, the Board shall, in lieu of such assumption or substitution,
provide for the Participant to have the right to exercise all Options or SARs
previously granted to such Participant, including Options or SARs which would
not otherwise be exercisable. If the Board makes an Option or SAR fully
exercisable in lieu of assumption or substitution in the event of a merger, the
Board shall notify the Participant that the Option or SAR shall be fully
exercisable for a period of fifteen (15) days from the date of such notice, and
the Option or SAR will terminate upon the expiration of such period. For the
purposes of this paragraph, the Option or SAR shall be considered assumed if,
following the merger, the Option or SAR, confers the right to purchase, or
receive the appreciation in Fair Market Value, as the

                                      -11-
<PAGE>   12

case may be, for each Share of stock subject to the Option or SAR immediately
prior to the merger, the consideration (whether stock, cash, or other securities
or property) received in the merger by holders of Common Stock for each Share
held on the effective date of the transaction (and if holders were offered a
choice of consideration, the type of consideration chosen by the holders of a
majority of the outstanding Shares); provided, however, that if such
consideration received in the merger was not solely common stock of the
successor corporation or its Parent, the Board may, with the consent of the
successor corporation and the participant, provide for the consideration to be
received upon the exercise of the Option or SAR, for each Share of stock subject
to the Option or SAR, to be solely common stock of the successor corporation or
its Parent equal in Fair Market Value to the per share consideration received by
holders of Common Stock in the merger or sale of assets.

         14. Time of Granting Options. The date of grant of an Option or SAR
shall, for all purposes, be the date on which the Administrator makes the
determination granting such Option or SAR, or such other date as is determined
by the Board. Notice of the determination shall be given to each Employee or
Consultant to whom an Option or SAR is so granted within a reasonable time after
the date of such grant.

         15. Amendment and Termination of the Plan.

                  (a) Amendment and Termination. The Board may at any time
amend, alter, suspend or discontinue the Plan, but no amendment, alteration,
suspension or discontinuation shall be made which would impair the rights of any
Participant under any grant theretofore made, without his or her consent. In
addition, to the extent necessary and desirable to comply with Rule 16b-3 under
the Exchange Act or with Section 422 of the Code (or any other applicable law or
regulation, including the requirements of the NASD or an established stock
exchange), the Company shall obtain shareholder approval of any Plan amendment
in such a manner and to such a degree as required.

                  (b) Effect of Amendment or Termination. Any such amendment or
termination of the Plan shall not affect Options or SARs already granted and
such Options or SARs shall remain in full force and effect as if this Plan had
not been amended or terminated, unless mutually agreed otherwise between the
Participant and the Board, which agreement must be in writing and signed by the
Participant and the Company.

         16. Conditions Upon Issuance of Shares. Shares shall not be issued
pursuant to the exercise of an Option or SAR unless the exercise of such Option
or SAR and the issuance and delivery of such Shares pursuant thereto shall
comply with all relevant provisions of law, including, without limitation, the
Securities Act of 1933, as amended, the Exchange Act, the rules and regulations
promulgated thereunder, and the requirements of any stock exchange upon which
the Shares may then be listed, and shall be further subject to the approval of
counsel for the Company with respect to such compliance.

                                      -12-
<PAGE>   13

                  As a condition to the exercise of an Option or SAR, the
Company may require the person exercising such Option or SAR to represent and
warrant at the time of any such exercise that the Shares are being purchased
only for investment and without any present intention to sell or distribute such
Shares if, in the opinion of counsel for the Company, such a representation is
required by any of the aforementioned relevant provisions of law.

         17. Reservation of Shares. The Company, during the term of this Plan,
will at all times reserve and keep available such number of Shares as shall be
sufficient to satisfy the requirements of the Plan.

                  The inability of the Company to obtain authority from any
regulatory body having jurisdiction, which authority is deemed by the Company's
counsel to be necessary to the lawful issuance and sale of any Shares hereunder,
shall relieve the Company of any liability in respect of the failure to issue or
sell such Shares as to which such requisite authority shall not have been
obtained.

         18. Agreements. Options, stock grants, stock purchase rights and SARs
shall be evidenced by written agreements in such form as the Administrator shall
approve from time to time.

         19. Shareholder Approval. Continuance of the Plan shall be subject to
approval by the shareholders of the Company within twelve (12) months before or
after the date the Plan is adopted. Such shareholder approval shall be obtained
in the degree and manner required under applicable state and federal law.

         20. Information to Participants. The Company shall provide to each
Participant, during the period for which such Participant has one or more
Options or SARs outstanding, copies of all annual reports and other information
which are provided to all shareholders of the Company. The Company shall not be
required to provide such information if the issuance of Options or SARs under
the Plan is limited to key employees whose duties in connection with the Company
assure their access to equivalent information.

         21. Governing Law. The validity, constrictions and effect of the Plan,
agreements entered into pursuant to the Plan, and of any rules, regulations,
determinations or decisions made by the Administrator relating to the Plan or
such agreements, and the rights of any and all persons having or claiming to
have any interest therein or thereunder, shall be determined exclusively in
accordance with applicable federal laws and the laws of the state of Delaware,
without regard to its conflict of laws principles.

                                      -13-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}]]